High-intent questions about ibogaine, answered with evidence. Safety, cost, legality, preparation, what to expect. Not a sales pitch. Not a deterrent. Just the clearest answers we can give.
Yes — ibogaine carries real risks, and anyone who tells you otherwise is not being honest with you. The primary danger is cardiac: ibogaine prolongs the QT interval, which can trigger life-threatening arrhythmias in people with underlying heart conditions. Most documented fatalities involve unscreened patients or inadequate medical supervision.
The risks are manageable — but only in a setting with proper cardiac screening before the session and medical monitoring during it. Every legitimate ibogaine program requires a 12-lead EKG, a cardiologist review, and active cardiac monitoring throughout the session. If a clinic doesn't require cardiac screening, do not work with them.
Beyond cardiac risk, ibogaine is a powerful psychoactive experience lasting 24–36 hours. The psychological intensity is real and should not be minimized. Ibogaine is not appropriate for people with certain psychiatric diagnoses, active suicidality, or several other contraindications.
Read the full risk profile →As of the most recent literature review, approximately 30 ibogaine-related deaths have been documented globally. The majority involve cardiac events — most often in patients who were not screened for pre-existing QT prolongation or cardiac conditions before treatment.
Context matters here. A significant portion of documented deaths occurred in unmonitored settings, with contraindicated medications on board, or without any cardiac workup. The fatality rate in medically supervised programs with proper screening is substantially lower — though not zero.
Ibogaine's fatality record is part of the case for rigorous medical supervision — not a reason to avoid it categorically, and not something to wave away either.
Read the full safety record analysis →Iboga is the plant — Tabernanthe iboga, a shrub native to Central Africa, particularly Gabon. Its root bark contains dozens of alkaloids, of which ibogaine is the most studied and most pharmacologically active.
Ibogaine is a specific alkaloid extracted from iboga root bark. Most clinics outside of Bwiti-tradition ceremonial programs use pharmaceutical-grade ibogaine HCl (hydrochloride) — a purified, standardized extract that allows precise dosing.
The distinction matters when choosing a program. Full-spectrum iboga root bark contains compounds beyond ibogaine that may enhance or alter the experience; pharmaceutical ibogaine HCl offers more predictable pharmacokinetics and better cardiac monitoring. Neither is inherently superior — they represent different philosophies of how to work with the medicine.
Read the full explainer →No — and this is important to be clear about. The Stanford PTSD study showed 83% of veterans reporting significant improvement at six-month follow-up. That means roughly 1 in 6 did not. Other studies show similarly varied results across populations and conditions.
Non-response to ibogaine is real. Factors that appear to correlate with better outcomes include: strong preparation and intention-setting, quality integration support afterward, the right clinical setting, and absence of certain medications. But the honest answer is that researchers don't yet fully understand what predicts who responds.
Anyone who guarantees results is overselling. The existing evidence is genuinely promising — especially for opioid use disorder and treatment-resistant PTSD — but ibogaine is not a guaranteed cure for anything.
Yes. Non-negotiable. Every legitimate ibogaine program requires cardiac screening before any session. Ibogaine prolongs the QT interval — a measure of the heart's electrical cycle — and patients with pre-existing QT prolongation, certain arrhythmias, or structural heart disease face significantly elevated risk of fatal cardiac events during a session.
Standard cardiac screening includes a 12-lead EKG, review by a cardiologist, and basic bloodwork. Some programs also require a stress test or echocardiogram depending on age, medical history, and risk factors. Expect this to be required 1–4 weeks before your session date.
If a program offers to skip this step — for any reason — that is a red flag. Walk away.
Read the full cardiac screening guide →Almost certainly not without a washout period first. SSRIs, SNRIs, MAOIs, and several other antidepressants interact dangerously with ibogaine — through QT prolongation, serotonin syndrome risk, or by blunting ibogaine's effects. Most programs require a complete washout before treatment.
Washout timelines vary by medication. SSRIs typically require 2–4 weeks; fluoxetine (Prozac), due to its long half-life, often requires 4–6 weeks. MAOIs are the most serious concern and may require 2+ weeks. Do not stop psychiatric medications without working with your prescribing physician — abrupt discontinuation carries its own risks.
The preparation window for patients on antidepressants is often longer than people expect. Factor this into your timeline planning.
See the full medication list and washout windows →Yes — but the preparation process is significantly more involved than for most patients, and the timeline is longer than most people anticipate.
Both buprenorphine (Suboxone) and methadone are long-acting opioids with high receptor binding affinity. Before ibogaine can work as an opioid receptor reset, these medications need to be tapered off and cleared. Methadone, in particular, requires an extended taper and washout — often 6–8 weeks or more — because of its very long half-life.
This process should be done under medical supervision. Many people use short-acting opioids as a bridge during taper before completing the final washout before ibogaine. Your program's medical team should guide this process — do not attempt a cold-turkey cessation of methadone or Suboxone without supervision.
Read the full guide for MAT patients →The active ibogaine experience typically lasts 24–36 hours from administration to resolution. The acute visionary phase — intense visual and introspective experience — usually runs 8–12 hours. This is followed by an extended processing phase where the effects gradually taper but remain significant.
Most patients are not ready to stand up, eat normally, or engage meaningfully with the world until 24+ hours after dosing. The day following the session is typically spent resting and beginning to integrate what came up. Full programs at clinics usually run 5–10 days to accommodate this recovery arc.
Most ibogaine programs in Mexico — the primary destination for US-based patients — run $5,000–$20,000+ for an all-inclusive program. The wide range reflects real differences in what's included: accommodations, medical staff ratios, duration, integration support, pre- and post-session care, and the credentials of the team.
The cheapest option is rarely the right call when cardiac monitoring and medical supervision are non-negotiable components of a safe session. That said, expensive does not automatically mean better. The clinic directory and the guide to choosing a program can help you evaluate what you're actually paying for.
For veterans specifically: several nonprofits cover full or partial treatment costs. See the veteran funding guide.
Read the full cost breakdown →Most clinics run small groups of 2–6 patients simultaneously. Some offer individual or "private" sessions. The differences go deeper than price.
Group settings typically cost less, create a sense of community among participants, and some people find comfort in not being alone during the experience. The tradeoff: less individualized attention from medical and support staff during the session.
Solo sessions offer more dedicated attention, more privacy, and a setting calibrated entirely to one person. They typically cost more. For patients with complex medical histories or significant trauma, the additional monitoring may be worth it.
Neither is categorically better — it depends on your specific situation, what you're treating, your personality, and what the program actually delivers in each format.
Read the full comparison →No. Ibogaine is a Schedule I controlled substance under the Controlled Substances Act — the same schedule as heroin and LSD. This means it is classified as having no currently accepted medical use and a high potential for abuse. Possession, distribution, and administration are federal crimes.
This does not prevent American citizens from traveling to Mexico or other countries where ibogaine is legal to receive treatment. It also does not prevent researchers from studying ibogaine under DEA research exemptions. But it does mean no legal ibogaine treatment is available on US soil at this time.
This may change. Mississippi passed the first state-level ibogaine research bill in 2026. Federal movement is being driven by veteran advocacy groups and the results of the Stanford PTSD trial. Track current developments in the Policy Tracker.
See the full policy landscape →Yes. Ibogaine is unscheduled in Mexico — meaning it is neither controlled nor prohibited at the federal level. This is why the vast majority of ibogaine clinics serving American patients are located in Mexico, primarily in Baja California (Tijuana, Rosarito, Ensenada) — a short drive from San Diego.
Legal status in Mexico does not mean unregulated. Clinics operate under Mexican medical licensing requirements. Quality, safety standards, and medical supervision vary significantly between programs. Do your research before choosing a clinic.
Receiving ibogaine treatment in Mexico, where it is legal, is not a federal crime for US citizens. The Controlled Substances Act prohibits possession and distribution within US jurisdiction — not receipt of legal treatment abroad.
There is no credible history of US federal prosecution of individuals for undergoing ibogaine treatment in Mexico. That said: bringing ibogaine back into the United States would be a federal crime. Do not attempt this.
This is general information, not legal advice. Laws change, individual circumstances vary, and this site does not provide legal counsel.
Duration, physical effects, the visionary experience — and what happens in the hours and days after. The most important thing to read before you go.
Read the guide →The questions that separate a safe program from a dangerous one. What to ask before you book, what the red flags look like, and what good medical supervision actually means.
Read the guide →Peer-reviewed outcome data, what the Stanford PTSD study actually measured, and an honest read of where the evidence is strong and where it's still thin.
Explore the research →